Protocol for generation of lung adenocarcinoma organoids from clinical samples

Zhichao Li; Lei Yu; Dong Chen; Zhaoyue Meng; Wei Chen; Weiren Huang

doi:10.1016/j.xpro.2020.100239

Protocol for generation of lung adenocarcinoma organoids from clinical samples

STAR Protoc. 2020 Dec 28;2(1):100239. doi: 10.1016/j.xpro.2020.100239. eCollection 2021 Mar 19.

Authors

Zhichao Li^{1

2

3}, Lei Yu^{1

2

3}, Dong Chen¹, Zhaoyue Meng¹, Wei Chen^{1

2

3

4}, Weiren Huang^{1

2

3

5

4}

Affiliations

¹ Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China.
² International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China.
³ Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, Guangdong 518035, China.
⁴ The First Affiliated Hospital of Shantou University, Shantou, Guangdong 515041, China.
⁵ Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.

Abstract

Human cancer tissue-derived organoids maintain the mutational spectrum and histological characteristics of their parental tumors and thus provide a platform for predicting patients' responses to anticancer drugs. Here, we provide a fully detailed, step-by-step protocol to derive lung adenocarcinoma organoids from primary tumor tissues. Organoid lines can be generated with a success rate of 80% using our protocol. For complete details on the use and execution of this protocol, please refer to Li et al. (2020).

Keywords: Cancer; Cell Biology; Organoids.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung* / metabolism
Adenocarcinoma of Lung* / pathology
Cell Culture Techniques*
Humans
Lung Neoplasms* / metabolism
Lung Neoplasms* / pathology
Organoids* / metabolism
Organoids* / pathology
Tumor Cells, Cultured